Instrument Inactif

Communiqués RELIEF THERAPEUTICS Holding SA CINNOBER BOAT

Actions

0QKQ

CH0100191136

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting	16:08	AQ
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting	28/03	AQ
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria	22/03	AQ
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth	06/12	AQ
Relief Therapeutics Announces CEO Transition	23/11	AQ
Relief Therapeutics announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone	11/10/23	AQ
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update	18/09/23	AQ
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement	19/06/23	AQ
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares	03/05/23	EQ
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule	01/05/23	EQ
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders	28/04/23	EQ
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100	17/04/23	EQ
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update	14/04/23	EQ
Relief Therapeutics Announces Executive Leadership Team Change	05/04/23	EQ
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders	04/04/23	EQ
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board	03/04/23	EQ
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023	22/03/23	EQ
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting	17/03/23	EQ
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe	16/03/23	EQ
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™	15/03/23	EQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués RELIEF THERAPEUTICS Holding SA CINNOBER BOAT

Actions

0QKQ

CH0100191136

Communiqués

Filtres